ORGANON & CO (OGN) Stock News
NYSE:OGN - New York Stock Exchange, Inc. - US68622V1061 - Common Stock - Currency: USD
OGN Latest News, Press Relases and Analysis
Here are the top movers in Thursday's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Top stock movements in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session.
Organon Stock Tumbles To Record Low On Downgrades And Dividend Cut: Retail Optimism Persists
Organon shares sank 27% Thursday after slashing its dividend by over 90%, triggering analyst downgrades and investor concern. Some retail traders, however, remained upbeat, citing the company’s focus on debt reduction and long-term growth.
OGN Investors Have Opportunity to Join Organon & Co. Fraud Investigation with the Schall Law Firm
Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The market is filled with gapping stocks in Thursday's session.
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.
Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q1 But Stock Drops 23.5%
Pharmaceutical company Organon (NYSE:OGN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 6.7% year on year to $1.51 billion. Its non-GAAP profit of $1.02 per share was 14.2% above analysts’ consensus estimates.
These stocks are moving in today's pre-market session
Wondering what's happening in Thursday's pre-market session? Find an overview in this article.
Organon Reports Results for the First Quarter Ended March 31, 2025
Organon (OGN) Q1 Earnings: What To Expect
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market open. Here’s what investors should know.
Countdown to Organon (OGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Organon (OGN) Ascends But Remains Behind Market: Some Facts to Note
In the most recent trading session, Organon (OGN) closed at $12.20, indicating a +0.66% shift from the previous trading day.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ICLR
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
Organon (OGN) Laps the Stock Market: Here's Why
Organon (OGN) closed the most recent trading day at $11.30, moving +1.07% from the previous trading session.
Organon (OGN) Stock Moves -0.34%: What You Should Know
Organon (OGN) concluded the recent trading session at $14.51, signifying a -0.34% move from its prior day's close.
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
Organon (OGN) closed the most recent trading day at $14.56, moving -1.02% from the previous trading session.
MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO
/PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic...
